What does Delgocitinib (Anzupgo) do in plain English—and how does it work inside your body?
Delgocitinib is an FDA-regulated Janus Kinase Inhibitor (RxNorm RxCUI RXN-50222280-2517). Mechanistically, Acting as a topical-route janus kinase inhibitor moiety, Delgocitinib (NDC 50222-280, manufactured/labeled by LEO Pharma, Inc) regulates downstream signaling pathways proportional to 20 mg/g Cream titration and patient renal/hepatic reserve. [1][2].
When your doctor writes a prescription for Delgocitinib (RxNorm RxCUI RXN-50222280-2517, also dispensed under brand names including Anzupgo), the goal is to target the root physiological pathway driving your condition rather than just masking surface symptoms [1]. According to the official FDA DailyMed package insert, Acting as a topical-route janus kinase inhibitor moiety, Delgocitinib (NDC 50222-280, manufactured/labeled by LEO Pharma, Inc) regulates downstream signaling pathways proportional to 20 mg/g Cream titration and patient renal/hepatic reserve. [2].
Across real-world patient logs on dotMD (74% positive worth-it rating), patients do best when they understand both what the medication is doing on day 1 and how long it takes to reach steady-state protection [3].
Check the imprint code on your Delgocitinib tablet bottle and confirm with your pharmacist that it matches your prescribed strength (20 mg/g Cream, 20 mg).